Inicio>>Signaling Pathways>> MAPK Signaling>> Mixed Lineage Kinase>>TC13172

TC13172

Catalog No.GC34140

TC13172 es un inhibidor de la proteÍna similar al dominio de la quinasa de linaje mixto (MLKL) con un valor EC50 de 2 nM para las células HT-29.

Products are for research use only. Not for human use. We do not sell to patients.

TC13172 Chemical Structure

Cas No.: 2093393-05-4

Tamaño Precio Disponibilidad Cantidad
10mM (in 1mL DMSO)
354,00 $
Disponible
5mg
321,00 $
Disponible
10mg
506,00 $
Disponible
50mg
1.517,00 $
Disponible
100mg
2.436,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

TC13172 is a mixed lineage kinase domain-like protein (MLKL) inhibitor with an EC50 value of 2 nM for HT-29 cells.

The anti-necroptosis potency of TC13172 is evaluated in the HT-29 cell line, the EC50 value is 2±0.6 nM. TC13172 has an inhibition potency of 2 nM against cell necroptosis. TC13172 inhibits MLKL by directly binding to Cys-86. TC13172 does not disrupt the phosphorylation of MLKL, but do decrease the level of MLKL in the membrane phase, demonstrating that these MLKL inhibitors block the translocation of MLKL to the cell membrane, thereby protecting cells from necroptosis[1].

[1]. Bo Yan, et al. Discovery of a new class of highly potent necroptosis inhibitors targeting the mixed lineage kinase domain-like protein.ChemCommun (Camb). 2017 Mar 28;53(26):3637-3640.

Reseñas

Review for TC13172

Average Rating: 5 ★★★★★ (Based on Reviews and 31 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for TC13172

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.